Tretinoin

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Tretinoin
Generic name
TRETINOIN
Manufacturer
Viona Pharmaceuticals Inc
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
946e67e7-458e-4607-b5f9-d5f6e021f7bd
SPL ID
22150db5-d543-419f-bc09-a3280e19777b
Version
1
Effective date
2026-09-30
Source export date
2026-11-13
Source partition
12
Source file
https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:55:16
Harmonized routes table
Harmonized routes
TOPICAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS Keep out of reach of children. Keep tube tightly closed. Do not expose to heat. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between l5°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS The skin of certain sensitive individuals may become excessively red, edematous, blistered or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin. To date, all adverse effects of tretinoin have been reversible upon discontinuance of therapy (see DOSAGE AND ADMINISTRATION ). To report SUSPECTED ADVERSE REACTIONS, contact Viona Pharmaceuticals Inc., at 1-888-304-5011 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.